Because evidence suggests that both Src and FAK mediate the aggressive behavior of pancreatic cancer cells and that they form a dual signaling pathway (Figs. 5 and 6), it might be beneficial to study whether a combination of Src and FAK inhibitors, with or without other current therapeutic agents, will enhance their overall efficacy to limit pancreatic cancer progression in vivo. This evidence concerns the gene SRC and familial pancreatic carcinoma.